Methazolamide, a sulfonamide derivative, is a white crystalline powder, weakly acidic, slightly soluble in water, alcohol and acetone.
Methazolamide tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.
Clinical Trials Related to Methazolamide
Safety Evaluation of Aminophylline and Methazolamide [Completed]
Rapid Acclimatization to Hypoxia at Altitude [Completed]
In low oxygen environments, such as altitude, some adults may become ill and suffer from
acute mountain sickness. Further, all adults will find that exercising becomes much more
difficult when compared with exercise at lower altitudes (e. g. sea-level). The purpose of
this investigation is to study the effects of two drugs that may help people adjust to
high-altitude quickly, prevent them from becoming ill and improve their exercise
performance. The drugs are Methazolamide and Aminophylline.
Three New Ideas to Protect Special Forces From the Stress of High Altitude [Recruiting]
Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of
non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric
pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS.
Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and
difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance
and endurance exercise capacity are impaired. Therefore, the goal of this research is to
identify effective pharmacological agents that will help reduce the symptoms of AMS and
improve physical and cognitive performance at high altitude.
The investigators will study the efficacy of the dietary supplement, quercetin, the drugs
nifedipine (extended release) and methazolamide taken together, and the drug metformin in
reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.
Stop Retinal Ganglion Cell Dysfunction Study [Recruiting]
Glaucoma is a progressive disease resulting in blindness. Determining the onset of the
disease, predicting its severity and the benefit of pressure lowering eye drops is key to
clinical management aimed at maintaining useful vision with advancing age. This study will
longitudinally monitor a population of glaucoma suspects (with positive factors for the
disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other
standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells
(RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before
dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with
abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG
will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography
(OCT) and other ancillary tests every 6 months over 4 years.
Improving Tumor Oxygenation in Cervical Cancer [Withdrawn]
The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with
ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are
affected adversely by acidic pH. These effects have primarily been attributed to the
presence of hypoxic cells within the tumor. The relevance of hypoxia with respect to
failure of radiotherapy to cure certain malignancies has had a chequered history. However,
in recent years the evidence that hypoxia plays a central role in relative radioresistance
has become more compelling.
Since approximately two-thirds of all women suffering from cervical carcinoma receive
radiation as a component of their therapy, an enhanced understanding of the interactions
between hypoxia and radiation as a component of their therapy, an enhanced understanding of
the interactions between hypoxia and radiation resistance is critical to improving outcome
among those with cervical cancer.
Page last updated: 2013-12-30